Generic drug price-fixing suit is akin to earlier case, but ‘on steroids,’ prosecutor says

Taking stock of the drug industry, from the lab to the medicine chest

October 27, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT+ | BridgeBio study data on drug for rare form of muscular dystrophy could set up approval The oral drug, known as ribitol, is for one subtype of limb-girdle muscular dystrophy, a broad collection of over 30 genetic diseases. By Jason Mast STAT+ | Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern The company has previously encountered few serious safety concerns, despite dosing hundreds of patients across its clinical trials. By Jason Mast SCIENCE PHOTO LIBRARY STAT+ | CAR-T therapies from Cabaletta, Bristol Myers Squibb induce remissions in patients with autoimmune disorders Small trials add to evidence personalized cell therapies may prove to be curative for patients with serious autoimmune disorders. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser